ArticleMolecules (Basel, Switzerland)2020
Evaluation of Met-Val-Lys as a Renal Brush Border Enzyme-Cleavable Linker to Reduce Kidney Uptake of
Article in Molecules (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 26 citations in OpenAlex.
- Development of NOTA-based antibody-fragment labeling agent that reduces early renal radioactivity levels.EJNMMI radiopharmacy and chemistry · 2026Article
- Linker Chemistry in Radiopharmaceutical Design.Bioconjugate chemistry · 2026Review
- Functional Suitability Evaluation of Radioimmunoconjugates of Nanobodies against PD-L1 and HER2/neu for Tumor Theranostics.Sovremennye tekhnologii v meditsine · 2026Article
- Article
- New tactics in the design of theranostic radiotracers.Npj imaging · 2024Review
- First-in-human validation of enzymolysis clearance strategy for decreasing renal radioactivity using modified [European journal of nuclear medicine and molecular imaging · 2024Article
- Reduction of renal activity retention of radiolabeled albumin binding domain‑derived affinity proteins using a non‑residualizing label strategy compared with a cleavable glycine‑leucine‑glycine‑lysine‑linker.Molecular medicine reports · 2024Article
- Reducing kidney uptake of radiolabelled exendin-4 using variants of the renally cleavable linker MVK.EJNMMI radiopharmacy and chemistry · 2023Article
- Reduction of the Renal Radioactivity ofJournal of medicinal chemistry · 2023Article
- New Long-Acting [Journal of medicinal chemistry · 2023Article
- Preclinical Evaluation of a PSMA-Targeting Homodimer with an Optimized Linker for Imaging of Prostate Cancer.Molecules (Basel, Switzerland) · 2023Article
- Validation of Freshly Isolated Rat Renal Cells as a Tool for Preclinical Assessment of Radiolabeled Receptor-Specific Peptide Uptake in the Kidney.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Optimizing the Safety and Efficacy of Bio-Radiopharmaceuticals for Cancer Therapy.Pharmaceutics · 2023Article
- Synthesis and radiolabelling of PSMA-targeted derivatives containing GYK/MVK cleavable linkers.Royal Society open science · 2023Article
- Application of Cleavable Linkers to Improve Therapeutic Index of Radioligand Therapies.Molecules (Basel, Switzerland) · 2022Review
- Bismuth-213 for Targeted Radionuclide Therapy: From Atom to Bedside.Pharmaceutics · 2021Review
- Preparation and Biological Evaluation of [Molecules (Basel, Switzerland) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
High kidney uptake is a common feature of peptide-based radiopharmaceuticals, leading to reduced detection sensitivity for lesions adjacent to kidneys and lower maximum tolerated therapeutic dose. In this study, we evaluated if the Met-Val-Lys (MVK) linker could be used to lower kidney uptake of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.